NCCN Clinical Practice Guidelines in Oncology Symposium: Non-Small Cell Lung Cancer CME/CE
Corey J. Langer, MD; Todd L. Demmy, MD; David S. Ettinger, MD; Mark G. Kris, MD; Gregory A. Otterson, MD Author Information and Disclosures
Release Date: November 29, 2007; Valid for credit through November 29, 2008
| Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.3 ANCC contact hours |
 |
This program is based on highlights from a symposium hosted by Roswell Park Cancer Institute on September 17, 2007 in Buffalo, New York.
Contents of This CME/CE Activity
- Workup, Prognostic Factors, and MarkersCorey J. Langer, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Therapy for Stages I, IIA, IIB, and IIIA (T3, N1) Non-Small Cell Lung CancerTodd L. Demmy, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Treatment Options for Unresectable Stage III Non-Small Cell Lung CancerDavid S. Ettinger, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Neoadjuvant Combined Modality Therapy for Potentially Resectable Stage III Non-Small Cell Lung CancerMark G. Kris, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Management of Metastatic Non-Small Cell Lung CancerGregory A. Otterson, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2007 National Comprehensive Cancer Network
